PCV51 Health Utilities among Patients with Obstructive Hypertrophic Cardiomyopathy (oHCM): An Analysis of Patient Health-Related Quality of Life in the EXPLORER-HCM Trial

      Treatment with mavacamten significantly improved the New York Heart Association (NYHA) functional class in patients with obstructive hypertrophic cardiomyopathy (oHCM) in the EXPLORER-HCM clinical trial. This study assessed the effects of mavacamten on patient health-related quality of life (HRQoL) and estimated the utilities for health states defined by NYHA class for these patients.
      To read this article in full you will need to make a payment


      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect